NAS10026,816−5.70%S&P7,430−3.37%GOLD$4,105+0.80%BTC$75,995−5.48%VIX25.68+54.61%latest tape · as of 16:02 UTC
The Screen · Healthcare · Medical Instruments & Supplies
Solventum
SOLV · a US exchange · USD · Market cap $13.8B · 20,584 employees
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally.
FAIL · Does not pass the screen
89.35 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 16:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price89.35 USD at the 4 Nov 2026 close
Our value readFair vs our fair value, as of 4 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.80, read 2026-11-02
Ethical does not pass the values gate
Price89.35 USD
Fair value84.66
Ethical score10.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-11-05Read Distribution89.35+0.0% to today Markdown gives way to Distribution
2026-10-02Read Markdown89.32+0.0% to today Accumulation gives way to Markdown with volume flow in agreement
2026-09-13Read Accumulation87.65+1.9% to today ✓Markup gives way to Accumulation after a 6% rise in 4 weeks
2026-08-13Read Markup82.96+7.7% to today ✓Accumulation gives way to Markup with volume flow in agreement
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Solventum holds its Distribution at $89.35. The statistical read favours the sellers, held for 5 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 5 days
Price at the screen
$89.35
Valuation
9.95 trailing · 11.19 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.70
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.22%
Below 33%
Interest-bearing debt is 35.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
13.38%
Below 49%
Money owed to the company is 13.4% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Solventum's business is in a permissible area, but its interest-bearing debt is about 35% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SOLV's ethical verdict changes
Today SOLV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades above our $84.66 fair value estimate, moderate competitive moat, 2.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 5.5% above the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $84.66, with a range of $63.90 to $97.36, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Solventum fails debt test despite solid margins
Picture a hospital supplier whose kits keep operations running, yet the balance sheet carries more debt than the business can comfortably carry. We pass on Solventum because the shares sit 8 percent above our fair value and the ethical screen flags excessive leverage straight away.
Revenue is already shrinking 3 percent, the forward multiple of 11.5 times offers little cushion for that decline, and the 35 percent return on equity looks less impressive once the debt load is considered. A moderate moat and 17 percent profit margin do not offset the valuation gap or the red flag on the balance sheet.
Thirteen analysts may still lean buy with an 85 dollar median target, yet that consensus ignores both the cyclical pressure on healthcare spending and the leverage that tripped our screen. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SOLV trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$84.76+4.2%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$81.33+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markdown$81.33+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$81.33+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markdown$81.33-4.8%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markdown$85.41+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$85.41-0.5%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$85.81+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95.
2026-10-21Markdown$85.81-1.7%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (13 analysts) rates it buy, with a mean price target of $95.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
